Core Viewpoint - Butterfly Network, Inc. is set to report its third quarter 2025 financial results on October 31, 2025, before the market opens [1]. Company Announcement - The financial results will be presented by Joseph DeVivo, the President, Chief Executive Officer, and Chairman of the Board, along with Megan Carlson, the Interim Chief Financial Officer [1]. - A conference call and webcast will be held at 8:00 a.m. following the financial results announcement [1].

Core Insights - Butterfly Network has launched an AI-powered Gestational Age tool in Malawi and Uganda to enhance maternal and fetal health through improved access to ultrasound technology [1][4] - The tool allows lower-skilled healthcare workers to estimate gestational age quickly and accurately without requiring image interpretation or extensive training [4][5] - The initiative is part of Butterfly's broader commitment to advancing maternal health in under-resourced settings, supported by the Gates Foundation and developed in collaboration with the University of North Carolina [4][5] AI-Enabled Gestational Age Tool - The AI tool addresses the critical need for affordable ultrasound technology in low-resource settings, where 92% of maternal and neonatal mortality occurs in low- and middle-income countries [2] - It enables midwives and other healthcare providers to deliver timely care by determining the appropriate gestational age for necessary medical interventions [4] Milestone Achievements - Butterfly Network has successfully deployed 1,000 handheld ultrasound probes and trained over 1,050 healthcare providers in Sub-Saharan Africa from September 2022 to December 2024 [6] - As of July 2025, 1.8 million scans have been conducted, averaging 83,000 scans monthly, demonstrating significant integration of obstetrical ultrasound services in over 697 public health facilities [6] Positive Impact on Maternal Health - Preliminary data from Kenya indicates a significant increase in women seeking antenatal care before 24 weeks, with over 90% patient satisfaction reported [9] - In South Africa, there has been a notable reduction in stillbirths and maternal mortality, with 873 appropriate referrals made for higher-level care [10][11] - The average scan time for providers has been reduced to 1.3 minutes, with a high confidence level in detecting key maternal conditions post-training [12] Technological Advancements - The latest Butterfly device, iQ3, has been approved for use in South Africa and Kenya, enhancing the quality and accessibility of POCUS [7] - Butterfly's innovations have received multiple accolades, including the Best Medical Technology at the 2024 Prix Galien USA Awards, highlighting the company's commitment to advancing healthcare technology [14]

Group 1 - Butterfly Network, Inc. (NYSE:BFLY) is recognized as a fundamentally strong penny stock, with Acadian Asset Management LLC increasing its stake by 270.5%, now holding 1,598,552 shares valued at $3,642,000 [1] - The second quarter of the fiscal year marked the highest quarterly revenue for Butterfly Network, with gross margins reaching an all-time high of 64% [2] - Analysts remain optimistic about Butterfly Network, with TD Cowen maintaining a 'Buy' rating and a price target of $3.50, driven by positive results from the POCUS-CARE trial [3] Group 2 - Butterfly Network, Inc. is a Massachusetts-based company focused on developing and commercializing ultrasound imaging solutions, founded in 2011 [4]

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - AGM Group Holdings Inc. (AGMH) increased by 185% to $6.36 [3] - AlphaVest Acquisition Corp (ATMV) rose by 77% to $26.80 [3] - Brera Holdings PLC (BREA) saw a 20% increase to $30.00 [3] - Asset Entities Inc. (ASST) gained 18% to $4.54 [3] - 22nd Century Group, Inc. (XXII) also increased by 18% to $2.08 [3] - Millennium Group International Holdings Limited (MGIH) rose by 16% to $2.84 [3] - Robo.ai Inc. (AIIO) increased by 11% to $2.17 [3] - Butterfly Network, Inc. (BFLY) saw a 10% rise to $2.10 [3] - GrafTech International Ltd. (EAF) increased by 9% to $13.91 [3] - Cardlytics, Inc. (CDLX) rose by 8% to $2.99 [3] Premarket Losers - ECD Automotive Design, Inc. (ECDA) decreased by 14% to $3.70 [4] - Champions Oncology, Inc. (CSBR) fell by 8% to $6.11 [4] - Beam Global (BEEM) saw an 8% decline to $2.79 [4] - Fathom Holdings Inc. (FTHM) decreased by 8% to $2.19 [4] - Ventyx Biosciences, Inc. (VTYX) fell by 7% to $2.20 [4] - SciSparc Ltd. (SPRC) decreased by 6% to $4.35 [4] - Lightwave Logic, Inc. (LWLG) fell by 6% to $3.45 [4] - Jasper Therapeutics, Inc. (JSPR) decreased by 6% to $2.43 [4] - StableX Technologies, Inc. (SBLX) fell by 5% to $5.67 [4] - Galecto, Inc. (GLTO) decreased by 5% to $2.70 [4]

Core Insights - Butterfly Network Inc. (BFLY) shares surged 14.81% to $2.17 in after-hours trading after being named to TIME's inaugural list of the World's Top HealthTech Companies for 2025 [1] - The company had already experienced a 15.95% increase during regular trading, closing at $1.89 [1] Company Recognition - Butterfly Network was selected from thousands of HealthTech companies, evaluated based on financial performance, reputation analysis, and online engagement data [2] - The recognition underscores the company's innovation in hardware and software, aiming to enhance ultrasound accessibility [3] Product Performance - The iQ3 device from Butterfly Network won the Best Medical Technology award at the 2024 Prix Galien USA Awards, highlighting its market impact [3] Market Performance - Despite a 39.42% loss for 2025 so far, BFLY has gained 36.96% in the past month [4] - The stock price peaked at $4.82 on February 18, 2025, but closed at $1.89, reflecting a 60.7% decrease [4] - BFLY trades within a 52-week range of $1.66 to $13.56, with a market capitalization of $475.79 million and an average daily volume of 2.91 million shares [4]

Core Insights - Several small-cap stocks experienced significant gains in after-hours trading, driven by strategic updates, leadership changes, and pipeline developments, indicating renewed investor interest [1] Adaptimmune Therapeutics plc (ADAP) - ADAP's stock surged 30% in after-hours trading, reaching $0.2020 after a 98% gain during the regular session, closing at $0.16 [2] - The company reported a net loss of $30.3 million for Q2 2025, with total revenue of $13.7 million, primarily from product sales of TECELRA, which saw over 150% growth compared to Q1 [3] - In August, Adaptimmune sold several cell therapies to US WorldMeds for $55 million upfront, with potential future milestone payments of up to $30 million, allowing the company to repay its debt and restructure [4] Butterfly Network Inc. (BFLY) - BFLY's stock rose 10.58% in after-hours trading to $2.09, following a 15.95% increase during the regular session [4] - The company was recognized in TIME's list of the World's Top HealthTech Companies for 2025, and appointed a new Chief Technology Officer, enhancing its focus on innovation [5] - A recent study confirmed that Butterfly-enabled POCUS programs significantly reduce hospital stays and costs, validating its clinical impact [5] Aquestive Therapeutics Inc. (AQST) - AQST's stock increased 7.69% in after-hours trading to $5.32, continuing a year-to-date rise of nearly 39% [6] - The FDA confirmed it will not require an advisory committee meeting for AQST's NDA for Anaphylm, streamlining the regulatory process with a PDUFA date set for January 2026 [7] - The company secured a $75 million strategic funding agreement to support the potential launch of Anaphylm, reinforcing its commercial readiness [7] ALX Oncology Holdings Inc. (ALXO) - ALXO's stock rose 9.17% in after-hours trading to $1.19, following a 3.81% increase during the regular session [8] - Insider buying activity, particularly by CEO Jason Lettmann, who purchased 92,233 shares, has boosted investor confidence [9] - The company's lead candidate, Evorpacept, is in multiple Phase 1 and Phase 2 trials across various cancers, collaborating with major partners [9] Ekso Bionics Holdings Inc. (EKSO) - EKSO's stock increased 5.37% in after-hours trading to $4.51, following a 9.74% gain during the regular session [10] - The company's inclusion in the NVIDIA Connect Program has spotlighted its efforts to integrate AI into its technologies [11] - EKSO launched Virtual eksoUniversity to support continuing education for physical therapists, potentially broadening adoption of its rehabilitation devices [11] CEL-SCI Corp. (CVM) - CVM's stock rose 5.27% in after-hours trading to $9.39, after a 1.02% increase during the regular session [12] - The company completed a $10 million public offering to support ongoing clinical and regulatory efforts [13] - CEL-SCI filed for Breakthrough Medicine Designation in Saudi Arabia for its lead candidate, Multikine, which could expedite patient access and reimbursement [13]

Group 1 - Butterfly Network Inc. (NYSE:BFLY) is recognized as a promising emerging technology stock due to its innovative handheld ultrasound device that connects to smartphones, utilizing patented ultrasound-on-a-chip technology [1][5] - The handheld ultrasound device is expected to make medical imaging more affordable, user-friendly, and accessible, particularly in clinics and developing countries, potentially disrupting traditional healthcare diagnostics [2][5] - TD Cowen analyst Josh Jennings has reaffirmed a Buy rating on Butterfly Network with a price target of $3.50, following positive results from the POCUS-CARE trial, which demonstrated the device's ability to reduce hospital costs and shorten patient stays [2][3] Group 2 - Jennings attributes the stock's nearly 30% decline since late July to temporary and cyclical headwinds identified during the Q2 2025 earnings call, suggesting that the pullback is excessive when considering Butterfly's long-term fundamentals [4] - With new clinical evidence supporting its technology, Butterfly Network is positioned to effectively implement its rollout strategy, reinforcing the Buy rating [5]

Company Announcement - Butterfly Network, Inc. has appointed Victor Ku as Senior Vice President and Chief Technology Officer (CTO) [1] - This appointment is seen as part of the company's efforts to improve its financial situation [1] Analyst Background - Gamu Dave Innocent Pasi is a financial professional with extensive experience in financial analysis and investment research [1] - He has a strong background in analyzing financial statements, capital markets, and macro-economics [1] - Pasi is recognized for providing actionable trading ideas and well-researched investment recommendations [1] - His insights have been featured in reputable publications, indicating a strong presence in the investment community [1] Investment Focus - Pasi is currently focused on building a new international investment portfolio [1] - He emphasizes the importance of innovative solutions that promote financial inclusion and sustainability [1] - Pasi advocates for Responsible Investment and actively incorporates Environmental, Social, and Governance (ESG) principles in investment decision-making [1]

Industry Overview - The global AI in healthcare market is projected to grow from $39.25 billion in 2025 to approximately $504.17 billion by 2032, at a CAGR of 44.0%, driven by demand for AI-enabled diagnostics, imaging, drug discovery, clinical workflow automation, and remote patient monitoring [1] Key Players and Innovations - Technology giants like NVIDIA are making significant moves in the healthcare space, collaborating with IQVIA to automate workflows in clinical research and life sciences, and partnering with GE HealthCare to enhance autonomous medical-device functions [3] - Palantir has partnered with TeleTracking to utilize its AI platform in hospitals for optimizing staffing workflows and improving patient care operations [4] - IonQ, AstraZeneca, AWS, and NVIDIA are collaborating on drug discovery, demonstrating a hybrid quantum-classical workflow that significantly speeds up pharmaceutical R&D [5] - IBM has introduced its advanced Quantum System Two, allowing research groups to utilize both classical and quantum computing for complex simulations [6] Investment Opportunities - Butterfly Network is advancing AI/ML in diagnostic imaging, reporting an AUROC of 0.94 in detecting aortic stenosis, and has launched an AI-powered training app for clinicians [8][10] - Omnicell is enhancing medication management with new products like MedTrack and MedVision, aimed at improving tracking, safety, and efficiency [14] - Both Butterfly Network and Omnicell are ranked as Buy stocks, with projected earnings growth of 29.4% and 12.9% respectively for 2025 and 2026 [9][15]

Core Insights - The study published in JAMA confirms that a Butterfly-enabled POCUS program focused on lung ultrasound significantly reduces hospital stay and costs associated with undifferentiated dyspnea, including acute heart-failure exacerbations [1][2][3]. Study Findings - The POCUS program led to a reduction of 246 hospital bed-days and resulted in direct cost savings of $751,537 during the evaluation period [3][4]. - The integration of a hospitalist POCUS workflow, which included lung ultrasound and AI assistance, was associated with a 30% reduction in expected hospital length of stay (8.3 days compared to 11.9 days, p = .01) [7]. - Clinical management was altered in 35% of cases due to the use of POCUS, highlighting its impact on patient care [7]. Economic Impact - The incremental cost-effectiveness ratio was calculated at $3,055 per hospital bed day saved, demonstrating the economic value of POCUS integration into inpatient care [7]. - The study emphasizes the potential for POCUS to improve hospital resource utilization and patient care through structured workflows [4][6]. Company Background - Butterfly Network, Inc. is a digital health company that specializes in portable ultrasound technology and software solutions, aiming to transform healthcare delivery [2][9]. - The company has developed a series of handheld ultrasound devices, including the Butterfly iQ, iQ+, and iQ3, which leverage advanced semiconductor technology [9][10].